

Simon Lovestone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7407281/publications.pdf>

Version: 2024-02-01

182
papers

18,393
citations

25014

57
h-index

16164

124
g-index

247
all docs

247
docs citations

247
times ranked

24835
citing authors

#	ARTICLE	IF	CITATIONS
1	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. <i>Nature Genetics</i> , 2013, 45, 1452-1458.	9.4	3,741
2	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
3	Rare coding variants in PLCC2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	9.4	783
4	Common genetic variants influence human subcortical brain structures. <i>Nature</i> , 2015, 520, 224-229.	13.7	772
5	Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. <i>Nature Neuroscience</i> , 2014, 17, 1164-1170.	7.1	488
6	Susceptibility Locus for Alzheimer's Disease on Chromosome 10. <i>Science</i> , 2000, 290, 2304-2305.	6.0	372
7	A Phase II Trial of Tideglusib in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 75-88.	1.2	363
8	Common brain disorders are associated with heritable patterns of apparent aging of the brain. <i>Nature Neuroscience</i> , 2019, 22, 1617-1623.	7.1	358
9	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , 2015, 138, 1327-1338.	3.7	284
10	Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. <i>Nature Genetics</i> , 1999, 21, 71-72.	9.4	260
11	The future of blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 115-131.	0.4	250
12	Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. <i>Lancet Neurology</i> , The, 2015, 14, 926-944.	4.9	227
13	Clusterin in Alzheimer's Disease: Mechanisms, Genetics, and Lessons From Other Pathologies. <i>Frontiers in Neuroscience</i> , 2019, 13, 164.	1.4	221
14	Novel genetic loci underlying human intracranial volume identified through genome-wide association. <i>Nature Neuroscience</i> , 2016, 19, 1569-1582.	7.1	213
15	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2015, 11, 549-560.	0.4	205
16	Clusterin regulates β -amyloid toxicity via Dickkopf-1-driven induction of the wnt/PCP/JNK pathway. <i>Molecular Psychiatry</i> , 2014, 19, 88-98.	4.1	197
17	AddNeuroMed™ The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2009, 1180, 36-46.	1.8	193
18	Genetic architecture of subcortical brain structures in 38,851 individuals. <i>Nature Genetics</i> , 2019, 51, 1624-1636.	9.4	192

#	ARTICLE	IF	CITATIONS
19	Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. <i>Alzheimer's and Dementia</i> , 2014, 10, 724-734.	0.4	182
20	Plasma proteins predict conversion to dementia from prodromal disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 799.	0.4	180
21	Convergent genetic and expression data implicate immunity in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 658-671.	0.4	173
22	Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. <i>Lancet Psychiatry</i> , 2016, 3, 179-186.	3.7	171
23	NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology. <i>Redox Biology</i> , 2017, 13, 444-451.	3.9	161
24	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e94661.	1.1	155
25	Association of blood lipids with Alzheimer's disease: A comprehensive lipidomics analysis. <i>Alzheimer's and Dementia</i> , 2017, 13, 140-151.	0.4	144
26	Developing novel blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 109-114.	0.4	138
27	Elevated DNA methylation across a 48 kb region spanning the <i>HOXA</i> gene cluster is associated with Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2018, 14, 1580-1588.	0.4	138
28	Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. <i>British Journal of Pharmacology</i> , 2001, 134, 1335-1343.	2.7	137
29	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , 2019, 15, 776-787.	0.4	134
30	Mitochondrial genes are altered in blood early in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 53, 36-47.	1.5	132
31	The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease : experience from the first 24 months. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 75-82.	1.3	127
32	Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. <i>Acta Neuropathologica Communications</i> , 2019, 7, 5.	2.4	125
33	MRI Measures of Alzheimer's Disease and the AddNeuroMed Study. <i>Annals of the New York Academy of Sciences</i> , 2009, 1180, 47-55.	1.8	121
34	The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume. <i>Neurobiology of Aging</i> , 2016, 40, 68-77.	1.5	115
35	Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer's disease brain. <i>Neurobiology of Aging</i> , 2014, 35, 1850-1854.	1.5	114
36	Development and Application of Ultra-Performance Liquid Chromatography-TOF MS for Precision Large Scale Urinary Metabolic Phenotyping. <i>Analytical Chemistry</i> , 2016, 88, 9004-9013.	3.2	113

#	ARTICLE	IF	CITATIONS
37	Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease. <i>JAMA Neurology</i> , 2020, 77, 164.	4.5	113
38	Heterogeneous patterns of brain atrophy in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 65, 98-108.	1.5	110
39	Circulating Proteomic Signatures of Chronological Age. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2015, 70, 809-816.	1.7	106
40	Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology. <i>Frontiers in Neurology</i> , 2015, 6, 236.	1.1	102
41	Long-term predictors of cognitive outcome in a cohort of older people with hypertension. <i>British Journal of Psychiatry</i> , 2000, 177, 66-71.	1.7	94
42	Identification of cis-regulatory variation influencing protein abundance levels in human plasma. <i>Human Molecular Genetics</i> , 2012, 21, 3719-3726.	1.4	94
43	Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. <i>Human Genetics</i> , 2001, 109, 646-652.	1.8	93
44	ϵ -2 macroglobulin gene and Alzheimer disease. <i>Nature Genetics</i> , 1999, 22, 17-19.	9.4	91
45	Sites of phosphorylation in tau and factors affecting their regulation. <i>Biochemical Society Symposia</i> , 2001, 67, 73-80.	2.7	91
46	The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. <i>Medical Image Analysis</i> , 2020, 66, 101714.	7.0	90
47	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , 2019, 18, 1034-1044.	4.9	85
48	Amyloid β 2 synaptotoxicity is Wnt/PCP dependent and blocked by fasudil. <i>Alzheimer's and Dementia</i> , 2018, 14, 306-317.	0.4	81
49	A Decade of Blood Biomarkers for Alzheimer's Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1181-1198.	1.2	80
50	Genetic Predisposition to Increased Blood Cholesterol and Triglyceride Lipid Levels and Risk of Alzheimer Disease: A Mendelian Randomization Analysis. <i>PLoS Medicine</i> , 2014, 11, e1001713.	3.9	75
51	Crowdsourced estimation of cognitive decline and resilience in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 645-653.	0.4	72
52	Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 809-817.	1.2	72
53	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 60, 92-103.	1.5	70
54	A metabolite-based machine learning approach to diagnose Alzheimer's type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 933-938.	1.8	70

#	ARTICLE	IF	CITATIONS
55	Automated Hippocampal Subfield Measures as Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease in Two Independent Cohorts. <i>Brain Topography</i> , 2015, 28, 746-759.	0.8	69
56	PET Tau and Amyloid- β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 283-293.	1.2	67
57	Disturbance of Notch-1 and Wnt signalling proteins in neuroglial balloon cells and abnormal large neurons in focal cortical dysplasia in human cortex. <i>Acta Neuropathologica</i> , 1999, 98, 465-472.	3.9	64
58	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019, 15, 817-827.	0.4	62
59	Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 20.	3.0	60
60	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. <i>Science Advances</i> , 2019, 5, eaau7220.	4.7	59
61	Predictors of care home and hospital admissions and their costs for older people with Alzheimer's disease: findings from a large London case register. <i>BMJ Open</i> , 2016, 6, e013591.	0.8	58
62	Alzheimer's disease in humans and other animals: A consequence of postreproductive life span and longevity rather than aging. <i>Alzheimer's and Dementia</i> , 2018, 14, 195-204.	0.4	58
63	The midlife cognitive profiles of adults at high risk of late-onset Alzheimer's disease: The PREVENT study. <i>Alzheimer's and Dementia</i> , 2017, 13, 1089-1097.	0.4	57
64	Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 26.	3.0	56
65	Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 612-621.	1.8	55
66	The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 85.	3.0	52
67	No Differences in Hippocampal Volume between Carriers and Non-Carriers of the ApoE ϵ 4 and ϵ 2 Alleles in Young Healthy Adolescents. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 37-43.	1.2	51
68	No association of salivary total tau concentration with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 70, 125-127.	1.5	51
69	An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. <i>Neurobiology of Aging</i> , 2020, 95, 26-45.	1.5	51
70	Blood protein predictors of brain amyloid for enrichment in clinical trials?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 48-60.	1.2	50
71	Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel ^{18}F -labelled PET tracer targeting P2X7. <i>EJNMMI Research</i> , 2017, 7, 31.	1.1	50
72	Cross-sectional and longitudinal analyses of outdoor air pollution exposure and cognitive function in UK Biobank. <i>Scientific Reports</i> , 2018, 8, 12089.	1.6	50

#	ARTICLE	IF	CITATIONS
73	Blood Protein Markers of Neocortical Amyloid- β^2 Burden: A Candidate Study Using SOMAscan Technology. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 947-961.	1.2	49
74	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. <i>Genome Biology</i> , 2021, 22, 90.	3.8	49
75	Stimulation of MAP kinase by v-raf transformation of fibroblasts fails to induce hyperphosphorylation of transfected tau. <i>FEBS Letters</i> , 1995, 365, 42-46.	1.3	46
76	Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. <i>BMJ Open</i> , 2016, 6, e012177.	0.8	46
77	Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer's disease. <i>Genome Medicine</i> , 2018, 10, 51.	3.6	46
78	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488.	0.4	46
79	Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 27-34.	1.2	44
80	The Effect of Age Correction on Multivariate Classification in Alzheimer's Disease, with a Focus on the Characteristics of Incorrectly and Correctly Classified Subjects. <i>Brain Topography</i> , 2016, 29, 296-307.	0.8	44
81	Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers. <i>Expert Review of Proteomics</i> , 2007, 4, 227-238.	1.3	43
82	A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 659-669.	1.2	43
83	Gait in Mild Alzheimer's Disease: Feasibility of Multi-Center Measurement in the Clinic and Home with Body-Worn Sensors: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 331-341.	1.2	42
84	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020, 10, 403.	2.4	42
85	Advanced glycation end products, dementia, and diabetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 4743-4744.	3.3	41
86	Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 561-572.	1.2	41
87	Complement Biomarkers as Predictors of Disease Progression in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 707-716.	1.2	41
88	Stability of graph theoretical measures in structural brain networks in Alzheimer's disease. <i>Scientific Reports</i> , 2018, 8, 11592.	1.6	41
89	Quantitative validation of a visual rating scale for frontal atrophy: associations with clinical status, APOE e4, CSF biomarkers and cognition. <i>European Radiology</i> , 2016, 26, 2597-2610.	2.3	39
90	Clusterin Is Required for β^2 -Amyloid Toxicity in Human iPSC-Derived Neurons. <i>Frontiers in Neuroscience</i> , 2018, 12, 504.	1.4	39

#	ARTICLE	IF	CITATIONS
91	Glycosylation of Human Plasma Clusterin Yields a Novel Candidate Biomarker of Alzheimer's Disease. <i>Journal of Proteome Research</i> , 2015, 14, 5063-5076.	1.8	36
92	The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 31.	3.0	36
93	A Multi-Cohort Study of ApoE ϵ 4 and Amyloid- β 2 Effects on the Hippocampus in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1159-1174.	1.2	36
94	CERAD Neuropsychological Compound Scores are Accurate in Detecting Prodromal Alzheimer's Disease: A Prospective AddNeuroMed Study. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 679-690.	1.2	35
95	Effects of FTDP-17 mutations on the in vitro phosphorylation of tau by glycogen synthase kinase 3 β identified by mass spectrometry demonstrate certain mutations exert long-range conformational changes. <i>FEBS Letters</i> , 2001, 493, 40-44.	1.3	34
96	Developing a new model for patient recruitment in mental health services: a cohort study using Electronic Health Records. <i>BMJ Open</i> , 2014, 4, e005654.	0.8	34
97	Differences in cohort study data affect external validation of artificial intelligence models for predictive diagnostics of dementia - lessons for translation into clinical practice. <i>EPMA Journal</i> , 2020, 11, 367-376.	3.3	34
98	Tau pathology in early Alzheimer's disease is linked to selective disruptions in neurophysiological network dynamics. <i>Neurobiology of Aging</i> , 2020, 92, 141-152.	1.5	34
99	Generalizability of the Disease State Index Prediction Model for Identifying Patients Progressing from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 79-92.	1.2	31
100	The human brainome: network analysis identifies HSPA2 as a novel Alzheimer's disease target. <i>Brain</i> , 2018, 141, 2721-2739.	3.7	31
101	Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 1105-1114.	1.2	30
102	Urinary metabolic phenotyping for Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 21745.	1.6	30
103	Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 145.	1.7	29
104	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 409.	1.7	28
105	Dysregulated Fc gamma receptor-mediated phagocytosis pathway in Alzheimer's disease: network-based gene expression analysis. <i>Neurobiology of Aging</i> , 2020, 88, 24-32.	1.5	28
106	APOE ϵ 4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 65.	3.0	28
107	The role of the father in parental postnatal mental health. <i>The British Journal of Medical Psychology</i> , 1995, 68, 157-168.	0.6	27
108	Down syndrome with and without dementia: An in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease. <i>NeuroImage</i> , 2011, 57, 63-68.	2.1	27

#	ARTICLE	IF	CITATIONS
109	Genetic and Real-World Clinical Data, Combined with Empirical Validation, Nominate Jak-Stat Signaling as a Target for Alzheimer's Disease Therapeutic Development. <i>Cells</i> , 2019, 8, 425.	1.8	27
110	Early diagnosis and the clinical genetics of Alzheimer's disease. <i>Journal of Neurology</i> , 1999, 246, 69-72.	1.8	26
111	A Subset of Cerebrospinal Fluid Proteins from a Multi-Analyte Panel Associated with Brain Atrophy, Disease Classification and Prediction in Alzheimer's Disease. <i>PLoS ONE</i> , 2015, 10, e0134368.	1.1	26
112	Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease 1. <i>Journal of Parkinson's Disease</i> , 2015, 5, 581-594.	1.5	25
113	The Notch intracellular domain represses CRE-dependent transcription. <i>Cellular Signalling</i> , 2015, 27, 621-629.	1.7	25
114	Differential effects of apolipoprotein E isoforms on phosphorylation at specific sites on tau by glycogen synthase kinase-3 β identified by nano-electrospray mass spectrometry. <i>FEBS Letters</i> , 2000, 485, 99-103.	1.3	24
115	Are premorbid abnormal personality traits associated with behavioural and psychological symptoms in dementia?. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 1050-1055.	1.3	23
116	A β ₄₂ /A β ₄₀ and A β ₄₂ /A β ₃₈ Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer's Disease: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1377-1383.	1.2	23
117	Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2020, 16, 1213-1223.	0.4	23
118	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021, 17, 1628-1640.	0.4	23
119	Apolipoprotein e genotype and late paraphrenia. <i>International Journal of Geriatric Psychiatry</i> , 1995, 10, 147-150.	1.3	22
120	Differential Associations of IL-4 With Hippocampal Subfields in Mild Cognitive Impairment and Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 439.	1.7	21
121	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. <i>Hippocampus</i> , 2017, 27, 653-667.	0.9	20
122	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 840651.	1.7	20
123	Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease. <i>BMJ Open</i> , 2019, 9, e024498.	0.8	18
124	Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 38.	3.0	18
125	ANMerge: A Comprehensive and Accessible Alzheimer's Disease Patient-Level Dataset. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 423-431.	1.2	18
126	Comorbidity between Alzheimer's disease and major depression: a behavioural and transcriptomic characterization study in mice. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 73.	3.0	18

#	ARTICLE	IF	CITATIONS
127	Tract Based Spatial Statistic Reveals No Differences in White Matter Microstructural Organization between Carriers and Non-Carriers of the APOE ϵ 4 and ϵ 2 Alleles in Young Healthy Adolescents. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 977-984.	1.2	17
128	Tackling gaps in developing life-changing treatments for dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 241-253.	1.8	17
129	UK Alzheimer's Disease Genetics Consortium. , 1999, 14, 789-791.		16
130	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 712545.	1.7	16
131	Boosting translational research on Alzheimer's disease in Europe: The Innovative Medicine Initiative AD research platform. <i>Alzheimer's and Dementia</i> , 2015, 11, 1121-1122.	0.4	15
132	Effects of freezer storage time on levels of complement biomarkers. <i>BMC Research Notes</i> , 2017, 10, 559.	0.6	15
133	Recruitment, Retainment, and Biomarkers of Response; A Pilot Trial of Lithium in Humans With Mild Cognitive Impairment. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 163.	1.4	15
134	Imaging $A\beta$ and tau in early stage Alzheimer's disease with [18F]AV45 and [18F]AV1451. <i>EJNMMI Research</i> , 2018, 8, 19.	1.1	14
135	Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach. <i>Computational and Structural Biotechnology Journal</i> , 2017, 15, 1-7.	1.9	13
136	Association of blood-based transcriptional risk scores with biomarkers for Alzheimer disease. <i>Neurology: Genetics</i> , 2020, 6, e517.	0.9	13
137	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 213-225.	1.2	13
138	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, 1452-1464.	0.4	13
139	A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 33.	3.0	11
140	Linking Genetics of Brain Changes to Alzheimer's Disease: Sparse Whole Genome Association Scan of Regional MRI Volumes in the ADNI and AddNeuroMed Cohorts. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 851-864.	1.2	10
141	No Genetic Overlap Between Circulating Iron Levels and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 85-99.	1.2	10
142	Minocycline 200mg or 400mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-62.	0.9	10
143	A missense variant in SHARPIN mediates Alzheimer's disease-specific brain damages. <i>Translational Psychiatry</i> , 2021, 11, 590.	2.4	10
144	Serum from Older Adults Increases Apoptosis and Molecular Aging Markers in Human Hippocampal Progenitor Cells. , 2021, 12, 2151.		10

#	ARTICLE	IF	CITATIONS
145	Acetylcholinesterase treatment?modelling potential demand and auditing practice. International Journal of Geriatric Psychiatry, 2001, 16, 1136-1142.	1.3	9
146	Hippocampal glutamate-glutamine (Glx) in adults with Down syndrome: a preliminary study using in vivo proton magnetic resonance spectroscopy (1H MRS). Journal of Neurodevelopmental Disorders, 2014, 6, 42.	1.5	9
147	Alleles that increase risk for type 2 diabetes mellitus are not associated with increased risk for Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2883.e3-2883.e10.	1.5	9
148	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. Molecular Psychiatry, 2022, 27, 1990-1999.	4.1	9
149	Editorial Review. The genetics of Alzheimer's disease? new opportunities and new challenges. International Journal of Geriatric Psychiatry, 1996, 11, 491-497.	1.3	8
150	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	1.2	7
151	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicine, 2021, 9, 1610.	1.4	7
152	A genetic test for Alzheimer's disease?. Psychiatric Bulletin, 1994, 18, 645-645.	0.3	5
153	Blood biomarkers for Alzheimer's disease. Genome Medicine, 2014, 6, 65.	3.6	4
154	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2023, 19, 807-820.	0.4	4
155	Genetics, molecular biology, neuropathology and phenotype of frontal lobe dementia. British Journal of Psychiatry, 2002, 180, 455-460.	1.7	3
156	No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 741-750.	1.2	2
157	[P4033]: DEEP AND FREQUENT PHENOTYPING: A FEASIBILITY STUDY FOR EXPERIMENTAL MEDICINE IN DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1268.	0.4	2
158	Effect of trazodone on cognitive decline in people with dementia: Cohort study using UK routinely collected data. International Journal of Geriatric Psychiatry, 2022, 37, .	1.3	2
159	Muscarinic therapies in Alzheimer's disease; from palliative treatments to disease modification. International Journal of Psychiatry in Clinical Practice, 1997, 1, 15-20.	1.2	1
160	Preface. Annals of the New York Academy of Sciences, 2009, 1180, vii-vii.	1.8	1
161	Trait, State, and Mechanism: Looking Back, Looking Forward, and Understanding Why. Journal of Alzheimer's Disease, 2012, 33, S23-S33.	1.2	1
162	[P212]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER'S DISEASE (EMIF-AD): THE BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2017, 13, P691.	0.4	1

#	ARTICLE	IF	CITATIONS
163	Proteomic analysis of Parkinson's disease patient cohorts show similarities in mechanism to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
164	Long life or old age? (Working with the elderly). <i>Psychiatric Bulletin</i> , 1992, 16, 168-168.	0.3	0
165	It takes Tau to tangle. <i>International Journal of Geriatric Psychiatry</i> , 1996, 11, 363-368.	1.3	0
166	Possible Future Treatments and Preventative Strategies for Alzheimer's Disease. , 0, , 325-326.		0
167	Biological Research on Dementias. , 0, , 287-322.		0
168	Neurogenetics: Scientific and Clinical Advances (Series: Neurological Disease and Therapy, Volume 75) Editor: DAVID R. LYNCH New York: Taylor & Francis, 2006, US\$198.95 Hardback, 755 pp. ISBN 0 8247 2942 0. <i>International Psychogeriatrics</i> , 2006, , 1.	0.6	0
169	Neurogenetics: Scientific and Clinical Advances (Series: Neurological Disease and Therapy, Volume 75) Editor: DAVID R. LYNCH New York: Taylor & Francis, 2006, US\$198.95 Hardback, 755 pp. ISBN 0 8247 2942 0. <i>International Psychogeriatrics</i> , 2007, 19, 337.	0.6	0
170	Genes of the serotonergic and dopaminergic pathways and their interaction affect the expression of Behavioural and Psychological Symptoms in Dementia (BPSD).. <i>Nature Precedings</i> , 2009, , .	0.1	0
171	O2-05-01: Clusterin, an amyloid chaperone protein in plasma is associated with longitudinal brain atrophy in mild cognitive impairment. , 2010, 6, S106-S107.		0
172	P3-113: NOVEL CANDIDATE BLOOD PROTEOME MARKERS OF ALZHEIMER'S DISEASE BRAIN AMYLOID BURDEN: A MULTIPLEX TMT-LC/MS-MS DISCOVERY APPROACH. , 2014, 10, P669-P670.		0
173	O3-04-03: CROSS-TISSUE METHYLOMIC PROFILING IN ALZHEIMER'S DISEASE. , 2014, 10, P215-P215.		0
174	Better together for better dementia research and care. <i>Lancet Psychiatry</i> ,the, 2016, 3, 503-504.	3.7	0
175	[P4"130]: "AMYLOID SYNAPTOTOXICITY DRIVES "AMYLOID PRODUCTION. <i>Alzheimer's and Dementia</i> , 2017, 13, P1306.	0.4	0
176	[P1"027]: PET TAU AND AMYLOID "BETA DIFFER IN THEIR RELATIONSHIP TO AGE, COGNITION AND CSF BIOMARKERS IN MILD ALZHEIMER'S DISEASE: AN OBSERVATIONAL STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P243.	0.4	0
177	[P3"051]: COULD COMPLEMENT INHIBITION BE A GOOD THERAPEUTIC TARGET IN ALZHEIMER'S DISEASE?. <i>Alzheimer's and Dementia</i> , 2017, 13, P950.	0.4	0
178	[P4"226]: BEST COMBINATORIAL LOW-COST MARKERS TO PREDICT MCI CONVERSION: AN EMIF "AD FEDERATION STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1356.	0.4	0
179	[P1"448]: PET TAU AND AMYLOID "BETA DIFFER IN THEIR RELATIONSHIP TO AGE, COGNITION AND CSF BIOMARKERS IN MILD ALZHEIMER'S DISEASE: AN OBSERVATIONAL STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P456.	0.4	0
180	[P2"223]: MARKERS OF CIRCADIAN CLOCK FUNCTION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P696.	0.4	0

#	ARTICLE	IF	CITATIONS
181	[F1â€“02â€“02]: DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER'S DÍSEASE PATHOLOGY AND PROGRESSION. Alzheimer's and Dementia, 2017, 13, P174.	0.4	0
182	Neurodegenerative Disorders - Mechanisms and Prospects for Therapy. Edited by D. L. Price, H. Thoenen and A. J. Aguayo Chichester: John Wiley & Sons. 1991. 301 pp. Â£50.00.. British Journal of Psychiatry, 1993, 162, 294-294.	1.7	0